Analysts update Alizyme
This article was originally published in Scrip
Piper Jaffrayanalysts have updated their forecast for Alizymeafter the company's second-half loss far exceeded expectations. Alizyme's net loss was £8.9 million, significantly higher than the £3.6 million predicted by the analysts (ScripOnline, September 1st, 2008). They reiterated their neutral recommendation as Alizyme ended the period with £7.7 million in cash, only slightly lower than their prediction of £8.4 million. However, the analysts reduced their price target from 10.1p to 8.1p and their forecast for Alizyme's year-end cash from £6.4 million to £2.6 million. Barring any further cost surprises, this should be enough to last the company until the end of next year, says Piper Jaffray.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.